The trending decline in alcohol consumption correlates with the adoption of GLP-1 weight management therapies. Recent pre-clinical and observational studies show that individuals on miracle weight loss drugs like Ozempic®, Wegovy®, or Maunjaro®, are choosing not to drink as much wine, beer, and cocktails as they used to. Studies show the same pathways that reduce appetite with GLP-1 can decrease the “pleasure” associated with drinking alcoholic beverages.
These studies are still in their infancy, but going alcohol-free is becoming more commonplace, with taste trends favoring complex profiles like herbal spritzers and spiced refreshers. Consumers are looking for new ways of “self-care” with indulgent ingestibles –now without alcohol. They aren’t turning to traditional sodas with their high sugar content and zero functional benefits either. Consumers are seeking interesting, “rewarding” beverage moments that provide.......